Physician profile
Michael Bobb
NPI 1588612006
$8,069.32
in general payments reported to CMS, 2019-2025
28 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,957 · 2020: $1,824 · 2021: $2,640 · 2022: $1,479 · 2023: $40.51 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $929.07 | 2019-2022 | |
| Abbvie INC. | $883.14 | 2020-2022 | |
| Novo Nordisk INC | $779.36 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $649.97 | 2019-2022 | |
| Lilly USA, LLC | $632.41 | 2019-2025 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $568.31 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $375.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $358.54 | 2019-2025 | Arexvy, Shingrix |
| Amgen INC. | $342.44 | 2019-2022 | |
| Pfizer INC. | $299.79 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $291.53 | 2019-2022 | |
| Allergan, INC. | $253.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $163.08 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $135.46 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.23 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $104.14 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $99.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $92.12 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $81.30 | 2022 | |
| Currax Pharmaceuticals LLC | $71.58 | 2021-2022 | |
| Eisai INC. | $67.55 | 2020-2021 | |
| Abbott Laboratories | $56.55 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.52 | 2019-2020 | |
| Lundbeck LLC | $45.66 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.99 | 2019-2020 | |
| Mylan Specialty L.P. | $20.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.